Affiliation:
1. Biosynexus Incorporated, Gaithersburg, Maryland 20877
Abstract
ABSTRACT
Lysostaphin is an endopeptidase that cleaves the pentaglycine cross-bridges of the staphylococcal cell wall rapidly lysing the bacteria. Recently, lysostaphin has been examined for its potential to treat infections and to clear
Staphylococcus aureus
nasal colonization, requiring a reliable method for determining the lysostaphin susceptibility of strains of
S. aureus
. We compared four methods for determining the lysostaphin susceptibility of 57 strains of methicillin-sensitive
S. aureus
, methicillin-resistant
S. aureus
, vancomycin intermediately susceptible
S. aureus
(VISA), mupirocin-resistant
S. aureus
, and various defined genetic mutants of
S. aureus
. Three reference lysostaphin-resistant
S. aureus
variants were also included in the assays as negative controls. The assays examined included turbidity, MIC, minimum bactericidal concentration (MBC), and disk diffusion assays. All of the strains of
S. aureus
tested, including a VISA strain which had previously been reported to be lysostaphin resistant, were susceptible to lysostaphin by all four methods. The three reference lysostaphin-resistant variants were resistant by all four methods. The disk diffusion assay was the simplest method to differentiate lysostaphin-susceptible
S. aureus
strains from lysostaphin-resistant variants, while the MBC assay could be used as a follow-up assay if required. In the disk diffusion assay, all strains of
S. aureus
tested revealed zones of inhibition of ≥11 mm using a 50-μg lysostaphin disk, while the three reference lysostaphin-resistant
S. aureus
variants had no zones of inhibition. In MBC assays, concentrations of lysostaphin ranging from 0.16 μg/ml to 2.5 μg/ml were found to cause a 3 log or greater drop from the initial CFU of
S. aureus
within 30 min for all strains tested.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference45 articles.
1. Avison, M., P. Bennett, R. Howe, and T. Walsh. 2002. Preliminary analysis of the genetic basis for vancomycin resistance in Staphylococcus aureus strain Mu50. J. Antimicrob. Chemother.49:255-260.
2. Boyle-Vavra, S., R. Carey, and R. Daum. 2001. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J. Antimicrob. Chemother.48:617-625.
3. Browder, H. P., W. A. Zygmunt, J. R. Young, and P. A. Travormina. 1965. Lysostaphin: enzymatic mode of action. Biochem. BioPhys. Res. Comm.19:383-389.
4. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin-United States, 2002. Morb. Mortal. Wkly. Rep.51:565-567.
5. Mechanism and Suppression of Lysostaphin Resistance in Oxacillin-Resistant
Staphylococcus aureus
Cited by
78 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献